Codexis Appoints Scott Watson as Vice President of Sales and Marketing

  Codexis Appoints Scott Watson as Vice President of Sales and Marketing

Business Wire

REDWOOD CITY, Calif. -- June 4, 2013

Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced the
appointment of Scott Watson as Vice President of Sales and Marketing,
effective May 2013. Mr. Watson has more than 25 years of experience in sales,
marketing and business development, including in the pharmaceutical and fine
chemicals markets.

“Scott brings a strong track record of success to Codexis, along with a wealth
of knowledge and connections from his various roles in the pharmaceutical and
fine chemical industries,” said John Nicols, President and CEO of Codexis. “We
continue to expand our pharmaceutical business through new collaborations with
strategic partners, and this hire will allow us to capitalize on the many
opportunities within both the pharmaceutical industry and other complex
chemistry markets where our tailored enzymes can provide significant benefits
for our customers.”

“Codexis is the world leader in developing biocatalysts for the pharmaceutical
industry and I am very excited to be joining the team at this time,” said
Scott Watson. “The opportunities in the pharmaceutical market continue to
grow, and I look forward to helping Codexis further expand its presence, in
pharmaceutical and other complex chemistry markets, during the coming years.”

Before joining Codexis, Mr. Watson served most recently as the Executive
Director of Sales and Marketing at AMPAC Fine Chemicals, a leading
manufacturer of custom small molecule active pharmaceutical ingredients. From
2008 to 2009, Mr. Watson served as Vice President of Sales and Marketing for
Girindus, a diverse service company to the pharmaceutical industry, where he
was responsible for realigning the company’s sales strategy. Prior to
Girindus, Mr. Watson held sales positions of growing responsibility with
various companies, including Aptuit, DSM and Eastman Chemical Company.

Mr. Watson is a former officer in the U.S. Navy and holds a B.S. in Chemistry
from the U.S. Naval Academy and an M.B.A. in Finance and Marketing from George
Mason University.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and implementation of
biocatalytic solutions to meet customer needs for rapid, cost-effective and
sustainable process development – from research to manufacturing. For more
information, see www.codexis.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to the
expansion of Codexis’ pharmaceutical business, Codexis’ abilities to
capitalize on business opportunities in the pharmaceutical and other markets
and the benefits that Codexis’ enzymes can provide its customers. You should
not place undue reliance on these forward-looking statements because they
involve known and unknown risks, uncertainties and other factors that are, in
some cases, beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results include Codexis’
dependence on a limited number of customers and a limited number of products
in its pharmaceutical business, Codexis’ abilities to develop and
commercialize new products for the pharmaceutical market, Codexis’ dependence
on its collaborators and the successful management of these relationships in
developing and commercializing new products, Codexis’ ability to deploy its
technology into market spaces adjacent to its pharmaceutical business and
Codexis’ customers receiving regulatory and market approval of their
pharmaceutical products.

Contact:

Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com
or
Media
Jemma Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk
 
Press spacebar to pause and continue. Press esc to stop.